Skip to main content

Advertisement

Table 1 Patient demographics and disease characteristics

From: Phase II trial of eribulin mesylate as a first- or second-line treatment for locally advanced or metastatic breast cancer: a multicenter, single-arm trial

  No. of patients %
Age, years
 Median 66
 Range 39–82
ECOG performance status
 0 25 78.1
 1 5 15.6
 2 2 6.3
(Neo-)adjuvant chemotherapy 22 68.7
 Anthracycline 7 21.9
 Taxane 2 6.3
 Anthracycline + taxan 11 34.4
 Oral 5FU 1 3.1
 CMF 1 3.1
Adjuvant endocrine therapy 14 43.7
Prior endocrine therapy for advanced disease 15 46.9
No. of prior chemotherapy regimens for advanced disease
 0 22 68.8
 1 10 31.3
 Taxan 5 15.6
 Oral 5FU (capecitabine or S-1) 5 15.6
ER-postive 19 59.4
PgR-positive 18 56.3
HER2-positive 1 3.1
Triple negatve 11 33.3
Metastatic site
 Liver 14 43.8
 Lung 14 43.8
 Brain 0 0
 Bone 13 40.6
 Skin 8 25
 Other 14 43.8
No of organs involved
 1 9 28.1
 2 13 40.6
 3 5 15.6
 4 5 15.6
Site of disease
 Viceral 23 71.9
  1. Abbreviations: ECOG Eastrern cooperative oncology group, ER estrogen receptor, PgR progesterone receptor, HER2 human epidermal growth factor receptor 2